$36.910
-0.358 (-0.97%)收盤時
HROW 資訊
HROW 事件
Harrow Reports Q2 Revenue of $70.66M, Exceeds Expectations
Reports Q2 revenue $70.66M, consensus $70.35M. "We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability," said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. "Over the past six months, we expanded our commercial organization, strengthened our portfolio, improved pricing across key products, launched BYOOVIZ(R), advanced multiple clinical programs, and announced the acquisition of TYRVAYA. VEVYE delivered record quarterly revenue while improving its underlying economics, and momentum continues to build, supported by our recent coverage win that went into effect August 1. IHEEZO achieved the strongest commercial quarter in its history despite the loss of pass-through reimbursement, and TRIESENCE continued to generate exceptional demand growth - reinforcing our conviction that physician demand continues to strengthen across our portfolio."
Harrow and Samsung Bioepis Present Interim Data on SB11
Harrow and Samsung Bioepis presented interim data from a post-marketing surveillance study on SB11, a biosimilar referencing Lucentis, at the Annual Meeting of the American Society of Retina Specialists. The interim report includes data from 298 patients evaluating the real-world safety and efficacy of SB11. The study demonstrated a comparable safety profile to the reference product and showed clinically meaningful efficacy improvement in treatment-naive patients while maintaining efficacy in those switched from other anti-VEGF therapies. "We believe this post-marketing surveillance data further strengthens the clinical foundation supporting BYOOVIZ, reinforcing the confidence retina specialists can have in this biosimilar option - both in treatment-naive patients and those transitioning from other anti-VEGF therapies," said Mark Baum, CEO of Harrow.
Harrow Launches FDA-Approved Byooviz Biosimilar
Harrow announced the commercial launch of Byooviz, an FDA-approved biosimilar referencing Lucentisi and developed by Samsung Bioepis.
Harrow Launches BYOOVIZ Biosimilar
Harrow announced the commercial launch of BYOOVIZ, an FDA-approved biosimilar referencing LUCENTISi and developed by Samsung Bioepis. The launch follows Harrow's exclusive U.S. commercialization agreement with Samsung Bioepis, one of the world's leading biosimilar developers and manufacturers. Through this partnership, Harrow obtained exclusive U.S. rights to commercialize BYOOVIZ and OPUVIZ, an FDA-approved biosimilar referencing EYLEAii, further strengthening the Company's position in the rapidly growing retinal biologics market.
Energy and Basic Materials Propel S&P 500 to Record Highs
Sharp gains in Energy and Basic Materials helped power S&P 500 to fresh record highs to start the week, despite the continued uncertainty in the Middle East over the weekend, whereby President Trump has flatly rejected the latest proposals from Iran. ExxonMobilwas up by nearly 4% as WTI crude oil remained supported by the Straight of Hormuz shipping passage uncertainty, briefly topping the $100 per barrel mark. Precious Metals group was also very strong, with Silver prices rising for the fifth straight session toward $88 per ounce and Gold topping $4,750 per ounce - Newmont Miningtopped $120 per share in regular trading and extended its gains above $121 afterhours - the highest level in about a month. Communication Services sector buckled as shares of Alphabetfell 3%, though Semiconductors and Memory names remained strong - Nvidiatested record highs above $220 and Micronadded 7% to its meteoric 2026 rise, with a stock now up nearly 180% for the year.In the evening hours, S&P, e-minis and NASDAQ 100 contracts are both up 0.1%. The earnings season has fizzled to a trickle though traders will still tune in to high-profile results out of Applied Materialsand Ciscolater in the week.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Quantum Computingup 14.7%Harmonicup 13.6%SI-BONEup 11.9%GoProup 9.9%PACS Groupup 9.9%Super Groupup 5.8%DOWN AFTER EARNINGS -ZoomInfodown 28.5%Hims & Hersdown 12.2%Harrowdown 12.2%WEBTOON Entertainmentdown 12.1%AST SpaceMobiledown 11.3%Bakktdown 10.8%CleanSparkdown 10.5%Ramaco Resourcesdown 7.7%LENZ Therapeuticsdown 5.0%Rigetti Computingdown 1.3%ALSO LOWER -GitLabdown 8.0% after announcing reduction in force
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。